智翔金泰预计2025年净利亏损4.81亿元至5.87亿元

Core Viewpoint - Zhixiang Jintai (688443) forecasts a net profit loss of between 481 million to 587 million yuan for 2025, with a year-on-year reduction in losses by 26.32% to 39.71% [1] Group 1: Financial Performance - The company expects significant revenue growth compared to the previous year, primarily driven by steady sales of its first commercial product, Saliqi monoclonal antibody injection (Jinlixi) [1] - The revenue increase is also attributed to the recognition of licensing income from the GR1803 injection licensing and commercialization agreement [1] Group 2: Research and Development - The company maintains a high level of R&D investment as multiple products enter clinical research phases and core products advance to critical clinical trial stages [1] - There will be no share-based payment expenses in 2025 due to the expiration of the equity incentive plan for the core team implemented in 2022, leading to a reduction in corresponding expenses [1] Group 3: Overall Outlook - Despite the anticipated net loss for 2025, the company expects a significant narrowing of the loss compared to the previous year [1]